BNP PARIBAS ASSET MANAGEMENT Holding S.A. Cuts Stake in Moderna, Inc. $MRNA

BNP PARIBAS ASSET MANAGEMENT Holding S.A. cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 70.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,703 shares of the company’s stock after selling 66,213 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Moderna were worth $712,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of MRNA. AQR Capital Management LLC purchased a new position in Moderna in the first quarter valued at $415,000. NewEdge Advisors LLC raised its position in Moderna by 732.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock valued at $328,000 after purchasing an additional 10,185 shares in the last quarter. United Services Automobile Association purchased a new position in shares of Moderna in the 1st quarter valued at about $230,000. Focus Partners Wealth grew its position in shares of Moderna by 58.7% during the first quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock worth $668,000 after buying an additional 8,706 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Moderna by 20.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 18,454 shares of the company’s stock worth $529,000 after buying an additional 3,074 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on MRNA shares. Barclays initiated coverage on shares of Moderna in a report on Wednesday, January 28th. They set an “equal weight” rating and a $25.00 price target for the company. Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research report on Monday, January 5th. TD Cowen reissued a “hold” rating on shares of Moderna in a report on Thursday, January 29th. The Goldman Sachs Group raised their price target on Moderna from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $17.00 price objective on shares of Moderna in a research report on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, Moderna has an average rating of “Reduce” and a consensus target price of $31.47.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA will review Moderna’s mRNA flu vaccine application after an initial refusal-to-file, with regulators now targeting a decision by Aug. 5, 2026 — a reversal that boosts the commercial outlook for a new recurring vaccine market and spurred an earlier jump in the stock. Moderna Stock Jumps After FDA Reverses Course on Flu Shot
• Positive Sentiment: Goldman Sachs analyst flagged upside for MRNA, an institutional vote of confidence that can support sentiment and buying interest. Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
• Neutral Sentiment: Moderna will present at TD Cowen and Barclays healthcare conferences in March — routine investor access that may provide more management detail but is unlikely by itself to move the stock dramatically. Moderna to Present at Upcoming Conferences in March 2026
• Negative Sentiment: BioNTech sued Moderna in Delaware federal court alleging Moderna’s mNexspike infringes a patent tied to BioNTech/Pfizer’s Comirnaty—new litigation increases legal risk, potential damages or injunctions, and heightens competitive/legal uncertainty for Moderna’s COVID-19/respiratory vaccine portfolio. BioNTech sues Moderna for patent infringement over COVID-19 shots
• Negative Sentiment: A court recently rejected two of Moderna’s defenses in its patent dispute with Arbutus, representing another legal setback that could increase exposure and costs from long-running mRNA technology litigation. Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Moderna Stock Performance

NASDAQ MRNA opened at $49.87 on Friday. The company has a fifty day moving average of $39.02 and a two-hundred day moving average of $30.44. The company has a market capitalization of $19.49 billion, a PE ratio of -6.86 and a beta of 1.32. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $55.20. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.29 and a quick ratio of 3.22.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, February 13th. The company reported ($2.11) EPS for the quarter, topping analysts’ consensus estimates of ($2.79) by $0.68. The business had revenue of $678.00 million for the quarter, compared to analysts’ expectations of $611.14 million. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The business’s revenue was down 33.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.91) earnings per share. As a group, analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the sale, the director directly owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.90% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.